Source:http://linkedlifedata.com/resource/pubmed/id/16123216
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
13
|
pubmed:dateCreated |
2005-12-5
|
pubmed:abstractText |
Immunophenotyping disclosed CD10 negativity in 70 of 2408 cases of B-lineage acute lymphoblastic leukemia (ALL), although other criteria followed classification of pre-B ALL (eg, cytoplasmic immunoglobulin positivity). These blasts showed high myeloid antigen expression (60% CD65 positivity) and reacted with antibody 7.1 in 95% of the cases. MLL-AF4 fusion transcripts or an 11q23/MLL rearrangement or both were evident in 46 of 56 samples (82%). Although 83% of the patients achieved complete remission, the remission duration remained remarkably low: 141 days for MLL rearrangement-positive and 245 days for MLL rearrangement-negative CD10(-) pre-B ALL. Thus, the overall survival probability 3 years after diagnosis was 0.34 +/- 0.20 SE in MLL-rearrangement-negative versus 0.12 +/- 0.06 SE in MLL rearrangement-positive CD10- pre-B ALL. Our data identify CD10- cytoplasmic immunoglobulin-positive pre-B ALL as a rare (2.2%) but distinct immuno-subtype of adult ALL that is characterized by a high MLL rearrangement rate and a worse outcome.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0006-4971
|
pubmed:author |
pubmed-author:ArnoldRenateR,
pubmed-author:BartramClaus RCR,
pubmed-author:DiedrichHelmutH,
pubmed-author:FonatschChristaC,
pubmed-author:GMALL Study Group,
pubmed-author:GleissnerBeateB,
pubmed-author:GoekbugetNicolaN,
pubmed-author:HeinzeBarbaraB,
pubmed-author:HoelzerDieterD,
pubmed-author:RiederHaraldH,
pubmed-author:SchochClaudiaC,
pubmed-author:SchwartzStefanS,
pubmed-author:ThielEckhardE
|
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
106
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
4054-6
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:16123216-Adolescent,
pubmed-meshheading:16123216-Adult,
pubmed-meshheading:16123216-Aged,
pubmed-meshheading:16123216-Chromosome Aberrations,
pubmed-meshheading:16123216-Chromosomes, Human, Pair 11,
pubmed-meshheading:16123216-Female,
pubmed-meshheading:16123216-Germany,
pubmed-meshheading:16123216-Humans,
pubmed-meshheading:16123216-Male,
pubmed-meshheading:16123216-Middle Aged,
pubmed-meshheading:16123216-Neprilysin,
pubmed-meshheading:16123216-Precursor Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:16123216-Risk Factors,
pubmed-meshheading:16123216-Survival Rate,
pubmed-meshheading:16123216-Transcription, Genetic,
pubmed-meshheading:16123216-Treatment Outcome
|
pubmed:year |
2005
|
pubmed:articleTitle |
CD10- pre-B acute lymphoblastic leukemia (ALL) is a distinct high-risk subgroup of adult ALL associated with a high frequency of MLL aberrations: results of the German Multicenter Trials for Adult ALL (GMALL).
|
pubmed:affiliation |
Department of Internal Medicine III, Campus Benjamin Franklin, Charité Universitätsmedizin, Hindenburgdamm 30, 12200 Berlin, Germany. beate.gleissner@charite.de
|
pubmed:publicationType |
Journal Article,
Multicenter Study
|